INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Innoviva, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$21.08+0.30 (+1.44%)
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- 5.2
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
74.8%
Operating margin
39.8%−55.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +14.7% | +7.5% | +4.1% | +22.5% | |
| Gross profit | +3.9% | – | – | – | |
| Operating income | -1.9% | – | -12.6% | +17.9% | |
| EPS, diluted | +816.7% | +11.7% | +10.3% | – | |
| Free cash flow | +3.9% | -1.0% | -9.0% | +34.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 9.88 | 55.98 | 14.64 | |
| Debt to equity | -2.03 | 0.71 | 0.22 | |
| Net debt to EBITDA | 4.86× | 0.42× | – | |
| Interest coverage | 2.1× | 17.5× | 9.8× | |
| Inventory turnover | – | – | 2.8× | |
| Capex to revenue | 0.2% | 0.0% | 0.3% | |
| Diluted shares | 123M | 114M | 85M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Innoviva generated $1.09B from operations and spent $499.57M on capital expenditure, dividends and share buybacks. 0% of that went back into the business.
Generated
$1.09B
Used
$499.57M
Capital expenditure$1.88M0%Dividends$00%Share buybacks$497.69M100%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero$196.93M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income$196.93M vs –
- Less leverageLong-term debt to assets fell19.7% → 15.8%
- Better liquidityCurrent ratio rose2.35 → 14.64
- No dilutionShare count did not rise74M → 85M
- Gross margin improvedGross margin up on the prior year82.58% → 74.80%
- More efficientAsset turnover rose0.29 → 0.32